<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04420481</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 2003-03-26</org_study_id>
    <nct_id>NCT04420481</nct_id>
  </id_info>
  <brief_title>Growth Hormone in Ischemic Heart Failure</brief_title>
  <official_title>Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a double-blind, placebo-controlled trial, we randomly assigned 37 patients (mean age 66&#xD;
      years; 95% male) with ischemic heart failure (HF) (ejection fraction (EF) &lt; 40%) to a 9-month&#xD;
      treatment with either recombinant human GH (1.4 mg every other day) or placebo, with&#xD;
      subsequent 3-month treatment-free follow-up. The primary outcome was change in left&#xD;
      ventricular (LV) end-systolic volume measured by cardiac magnetic resonance (CMR). Secondary&#xD;
      outcomes comprised changes in cardiac structure and EF. Prespecified tertiary outcomes&#xD;
      included changes in New York Heat Association (NYHA) functional class and quality of life&#xD;
      (QoL), as well as levels of insulin-like growth factor-1 (IGF-1) and N-terminal pro-brain&#xD;
      natriuretic peptide (NT-proBNP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TITLE: GROWTH HORMONE IN HEART FAILURE Addition of recombinant human growth hormone to&#xD;
      standard heart failure therapy in patients with congestive heart failure due to ischaemic&#xD;
      heart disease.&#xD;
&#xD;
      A 12 month study, consisting of a 9 month double-blind, placebo-controlled randomised growth&#xD;
      hormone treatment phase followed by a 3 month growth hormone treatment-free period.&#xD;
&#xD;
      STUDY PHASE: III&#xD;
&#xD;
      COORDINATING CENTRE:&#xD;
&#xD;
      Endocrine Cardiac Unit (ECU) Sahlgrenska University Hospital, Sahlgrenska S-413 45 Göteborg&#xD;
      Sweden&#xD;
&#xD;
      STUDY PRODUCT:&#xD;
&#xD;
      Somatropin, recombinant human growth hormone (rhGH), Saizen® 8 mg (24 IE).&#xD;
&#xD;
      CONTROL PRODUCT:&#xD;
&#xD;
      Placebo for Saizen®&#xD;
&#xD;
      DOSAGE OF STUDY PRODUCT:&#xD;
&#xD;
      1,4 mg (4,2 IE) every other day.&#xD;
&#xD;
      DOSAGE:&#xD;
&#xD;
      9 month treatment period and a 3 month follow-up period. ROUTE OF ADMINISTRATION One&#xD;
      subcutaneous injection of Saizen® of study product, or corresponding placebo in the thigh or&#xD;
      abdomen given in the evening given every other day.&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      Double-blind (regarding treatment), parallel, placebo-controlled, randomised.&#xD;
&#xD;
      STUDY POPULATION:&#xD;
&#xD;
      Female and male patients 75 years of age or below with congestive heart failure (NYHA class&#xD;
      II or III) due to ischemic heart disease.&#xD;
&#xD;
      NUMBER OF PATIENTs:&#xD;
&#xD;
      54 evaluable patients. MULTICENTRE: Yes. NUMBER OF CENTRES: Four&#xD;
&#xD;
      ALLOCATION OF TREATMENT:&#xD;
&#xD;
      Randomisation to treatment if all inclusion/exclusion criteria are met.&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      To investigate the effect of subcutaneously administered Saizen® compared with placebo on&#xD;
      left ventricular endsystolic volume by MRI in patients with congestive heart failure due to&#xD;
      ischaemic heart disease.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      To determine the effect of Saizen® on enddiastolic volume, left ventricular mass and left&#xD;
      ventricular ejection fraction&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      To determine the effect of Saizen® on change in NYHA class after 9 months of follow up.&#xD;
&#xD;
      To determine the effect of Saizen® on circulating levels of IGF-I and IGFBP-3 and to evaluate&#xD;
      the correlation between changes in IGF-I and the respective changes in left ventricular&#xD;
      ejection fraction, wall stress and left ventricular mass.&#xD;
&#xD;
      To evaluate the effect of Saizen® on quality of life by using two different questionnaires&#xD;
      (Minnesota - Living with Heart Failure and Cardiac Health Profile).&#xD;
&#xD;
      To determine the effect of Saizen® on neurohormonal activation by measuring NT-proBNP&#xD;
&#xD;
      SAFETY VARIABLES:&#xD;
&#xD;
      Hospitalization, morbidity and mortality.&#xD;
&#xD;
        -  Clinical events, including tendency to fluid retention, glucose intolerance, arrhythmias&#xD;
           and worsening heart failure.&#xD;
&#xD;
        -  Electrolytes, haematology, prothrombin complex, parameters for renal and hepatic&#xD;
           function.&#xD;
&#xD;
      ADVERSE EVENTS:&#xD;
&#xD;
      Spontaneously reported from patients and asked for. To be recorded in Case Report Forms&#xD;
      (CRFs) and on separate Adverse Event form if serious Adverse Event.&#xD;
&#xD;
      STATISTICS AND DATABASE MANAGEMENT:&#xD;
&#xD;
      Data management will be performed by Scandinavian Contract Research Institute and when clean&#xD;
      file is declared data will be made available to the statistician for the analysis. The&#xD;
      analysis will be performed according to the intention to treat principle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2004</start_date>
  <completion_date type="Actual">February 25, 2012</completion_date>
  <primary_completion_date type="Actual">February 25, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A 12 month study, consisting of a 9 months' double-blind, placebo-controlled randomised growth hormone treatment phase followed by a 3 months' growth hormone treatment-free period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All care providers and patients were masked with respect to the study drug during the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular endsystolic volume</measure>
    <time_frame>9 months</time_frame>
    <description>Measured by CMR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in enddiastolic volume</measure>
    <time_frame>9 months</time_frame>
    <description>Measured by CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular mass</measure>
    <time_frame>9 months</time_frame>
    <description>Measured by CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>9 months</time_frame>
    <description>Measured by CMR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in QoL Questionnaire</measure>
    <time_frame>9 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in NT-proBNP level</measure>
    <time_frame>9 months</time_frame>
    <description>blood sample</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Ischemic Heart Disease Chronic</condition>
  <arm_group>
    <arm_group_label>Growth hormon group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.</description>
    <arm_group_label>Growth hormon group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ejection fraction at rest less than 40% at the screening visit as measured by&#xD;
             echocardiography and a left ventricular enddiastolic diameter &gt; 32 mm/m2&#xD;
&#xD;
          -  Stable, optimised therapy for heart failure for at least 4 weeks prior to&#xD;
             randomisation including Angiotensin converting enzyme inhibitors, or if not tolerated,&#xD;
             angiotensin II blockers and/or digitalis. If tolerated patients should receive&#xD;
             beta-blockers for heart failure provided they have had a stable dose for at least 3&#xD;
             months prior to randomisation. The dose of diuretics may vary within a given&#xD;
             dose-range considered normal for that patient as determined by the investigator.&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension, treated or not treated with a diastolic blood pressure &gt;105&#xD;
             mm Hg&#xD;
&#xD;
          -  Haemodynamic clinically significant primary valvular disease or significant congenital&#xD;
             heart disease&#xD;
&#xD;
          -  Hypertrophic or idiopathic dilated cardiomyopathy&#xD;
&#xD;
          -  Acute pericarditis/myocarditis&#xD;
&#xD;
          -  Echocardiography findings such as mobile thrombus, significant pericardial effusion&#xD;
             and significant left ventricular aneurysm&#xD;
&#xD;
          -  Symptomatic or sustained ventricular arrhythmias within the last 3 months not&#xD;
             adequately treated with antiarrhythmic drugs or internal cardiovertor defibrillator&#xD;
             (ICD)&#xD;
&#xD;
          -  Unstable angina pectoris, or myocardial infarction within last 3 months&#xD;
&#xD;
          -  percutaneous coronary intervention performed within 6 months prior to randomization&#xD;
&#xD;
          -  Planned percutaneous coronary intervention, heart transplantation, other cardiac&#xD;
             surgery or other major surgery&#xD;
&#xD;
          -  Atrial fibrillation, if a frequency &gt; 100/min or a large frequency variation,&#xD;
             according to clinical judgment&#xD;
&#xD;
          -  Diabetes mellitus, insulin treated&#xD;
&#xD;
          -  Severe liver disease (alanine aminotransferase and/or alanine aminotransferase three&#xD;
             times upper limit of normal range laboratory values)&#xD;
&#xD;
          -  Severely reduced renal function (S-Creatinine above 250 micromol/l) or suspected&#xD;
             significant renal artery stenosis&#xD;
&#xD;
          -  Uncontrolled endocrine disorders&#xD;
&#xD;
          -  Ongoing treatment with calcium antagonist&#xD;
&#xD;
          -  Pregnancy or lactation or females of childbearing potential taking inadequate measures&#xD;
             to prevent pregnancy&#xD;
&#xD;
          -  History of or ongoing malignant disease&#xD;
&#xD;
          -  Previous treatment with growth hormone&#xD;
&#xD;
          -  Patients in a catabolic state&#xD;
&#xD;
          -  Known drug and/or alcohol abuse&#xD;
&#xD;
          -  Inability to cooperate or administer the study drug&#xD;
&#xD;
          -  Patients participating in any other clinical study, within 30 days prior to screening&#xD;
             visit and/or during this particular study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, Systolic</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <keyword>Growth Hormone Treatment</keyword>
  <keyword>Insulin Growth Factor I Resistance</keyword>
  <keyword>Hormone Disturbance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be share upon reasonable request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3 months</ipd_time_frame>
    <ipd_access_criteria>A researcher that can show previous scientific merits that can be validated</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

